Recommended Articles
Fundraising

RougeTx Emerges From Stealth With $58M Series A to Target Rare Bleeding Disorder HHT

By Angeled · October 7, 2026 · Fundraising
RougeTx Emerges From Stealth With $58M Series A to Target Rare Bleeding Disorder HHT
RougeTx Emerges From Stealth With $58M Series A to Target Rare Bleeding Disorder HHT

The RougeTx Series A marks one of the boldest European biotech launches of the year. On October 6, 2026, the Netherlands-based company — headquartered in Naarden — emerged from stealth with a $58 million Series A round aimed at developing RTX-001, a first-in-class therapy for hereditary hemorrhagic telangiectasia (HHT), an inherited disorder with no approved therapies.

The round was co-led by BioGeneration Ventures, Angelini Ventures, and Kurma Partners, with support from the European Investment Bank's Aurea co-investment facility. Additional participants included Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures.

What RougeTx Is Building

Hereditary hemorrhagic telangiectasia causes abnormal blood-vessel formation and recurrent, often severe bleeding. Patients can suffer nosebleeds, gastrointestinal bleeding, and dangerous arteriovenous malformations in organs like the lungs, liver, and brain. Today, there is no approved therapy designed specifically for HHT — care is limited to managing symptoms and procedures to control bleeding.

RougeTx's lead program, RTX-001, takes a different approach. Rather than targeting the endothelial cells that line blood vessels, the company's science focuses on pericytes — the cells that stabilize blood vessels by wrapping around them. RTX-001 is designed to restore the attachment of pericytes to endothelial cells, reinforcing the fragile, malformed vessels that define the disease.

Why Investors Wrote a $58M Check for a Preclinical Company

A $58 million Series A for a preclinical biotech is a large raise by any standard. Biotech investors know that the path from discovery to revenue runs through expensive toxicology studies, manufacturing scale-up, regulatory filings, and multi-phase clinical trials. What convinced this syndicate is the combination of a sharply defined unmet need, a novel biological mechanism, and a platform with legs.

Investors are betting that pericyte biology represents a genuinely differentiated approach to vascular disease. If RTX-001 can demonstrate that restoring pericyte attachment stabilizes vessels in HHT patients, the same mechanism could plausibly apply to a range of diseases characterized by unstable blood vessels — which is exactly what RougeTx's periSCOPE platform is built to explore.

The participation of the European Investment Bank's Aurea co-investment facility also signals growing European institutional support for homegrown biotech, at a time when many of the continent's most promising life-science companies have historically relocated or listed in the United States.

Why the RougeTx Series A Matters for Founders and Investors

For founders: RougeTx is a case study in how to launch in biotech today. The company waited until it could articulate a clear first indication (HHT), a differentiated mechanism (pericyte restoration), and a platform expansion story (periSCOPE) before raising — and the syndicate it assembled reads like a who's-who of European life-science capital. A tight narrative with a platform beyond the lead asset is what converts scientific promise into a $58M launch round.

For investors: The round reflects continued appetite for preclinical biotech with genuine biological novelty, even as generalist venture has pulled back from risk. The bar is high — no approved therapies exist, so clinical endpoints will need to be invented and validated — but the HHT indication offers a defined patient population, clear unmet need, and potential orphan-drug pathways that can de-risk development and commercialization.

The key milestone to watch: IND-enabling studies and the first-in-human trial. For a company at this stage, data — not fundraising — is the only currency that compounds.

Angeled.com connects founders with investors.

Read Next